18-12-7　ⓔ文献

  1. Hultcrantz M, Kristinsson SY, et al: Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population–based study. J Clin Oncol, 2012; 30: 2995–3001.

  2. 日本血液学会編：造血器腫瘍診療ガイドライン2018年版．http://www.jshem.or.jp/gui-hemali/index.html

  3. Barbui T, Barosi G, et al: Philadelphia–negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemia Net. J Clin Oncol, 2011; 29: 761–770.

  4. Hultcrantz M, Kristinsson SY, et al: Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population–based study. J Clin Oncol, 2012; 30: 2995–3001.

  5. 日本血液学会編：造血器腫瘍診療ガイドライン2018年版．http://www.jshem.or.jp/gui-hemali/1_4.html

  6. 日本血液学会編：造血器腫瘍診療ガイドライン2018年版．http://www.jshem.or.jp/gui-hemali/index.html

  7. Sanz MA, Lo Coco F, et al: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia : a joint study of the PETHEMA and GIMEMA cooperative groups. Blood, 2000; 96: 1247–1253.

  8. Tomita N, Yokoyama M, et al: The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis. Leuk Lymphoma, 2018; 59: 97–104.

  9. 日本血液学会編：造血器腫瘍診療ガイドライン2018年版．http://www.jshem.or.jp/gui-hemali/index.html

  10. 滑川道人：中枢神経系における悪性リンパ腫: overview. Brain Nerve, 2014; 66: 907–916.

  11. 日本血液学会編：造血器腫瘍診療ガイドライン2018年版．http://www.jshem.or.jp/gui-hemali/index.html

  12. 納　光弘，有村公良，他：Crow–Fukase症候群の全国疫学調査2004．厚生労働省免疫性疾患に関する調査研究班報告書，2005; 141–144.

  13. Dispenzieri A: POEMS syndrome : 2017 Update on diagnosis, risk stratification, and management. Am J Hematol, 2017; 92: 814–829.

  14. The portal for rare diseases and orphan drugs. https://www.orpha.net/consor

  15. 小嶋哲人：先天性凝固阻止因子欠乏症 (antithrombin, protein C, protein S欠損症) Congenital anticoagulant deficiency (antithrombin, protein C, protein S deficiency)．日本血栓止血学会誌，2009; 20: 484–486.